Cara Therapeutics Files 8-K for Financials

TL;DR

CARA filed an 8-K for financial results - check for updates.

AI Summary

Cara Therapeutics, Inc. filed an 8-K on May 13, 2024, reporting results of operations and financial condition, along with financial statements and exhibits. The filing does not contain specific dollar amounts or detailed operational updates within the provided text, but indicates a standard reporting event.

Why It Matters

This filing provides an update on Cara Therapeutics' financial condition and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any immediately disclosed material adverse events or significant new information beyond standard reporting requirements.

Key Players & Entities

• Cara Therapeutics, Inc. (company) — Filer of the 8-K
• May 13, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CARA The Nasdaq Stock Marke

Filing Documents

• tm2414193d1_8k.htm (8-K) — 24KB
• tm2414193d1_ex99-1.htm (EX-99.1) — 69KB
• tm2414193d1_ex99-1img001.jpg (GRAPHIC) — 5KB
• 0001104659-24-060529.txt ( ) — 279KB
• cara-20240513.xsd (EX-101.SCH) — 3KB
• cara-20240513_lab.xml (EX-101.LAB) — 33KB
• cara-20240513_pre.xml (EX-101.PRE) — 22KB
• tm2414193d1_8k_htm.xml (XML) — 4KB

02

Item 2.02. Results of Operations and Financial Condition. On May 13, 2024, Cara Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter ended March 31, 2024. A copy of the press release is being furnished to the Securities and Exchange Commission as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference to this Item 2.02. The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated May 13, 2024 104 Cover page interactive data file (formatted as Inline XBRL) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CARA THERAPEUTICS, INC. By: /s/ RYAN MAYNARD Ryan Maynard Chief Financial Officer (Principal Financial and Accounting Officer) Date: May 13, 2024 3

View Full Filing

View this 8-K filing on SEC EDGAR